Johnson & Johnson's pharmaceutical company Janssen has joined forces with Abdi Ibrahim as a strategic partner in the localization of its innovative portfolio. This collaboration is aimed at increasing Turkey’s local manufacturing capacity and competency and improving Turkey’s competitiveness in global markets. The project covers products used for the treatment of different types of cancers and rare diseases.
Janssen conducted clinical research investments worth approximately $40 million in Turkey in the last decade. With 8 new projects initiated in 2017, it became the 2nd company that initiated the highest number of new clinical studies in Turkey.